LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings.

Publication

Author(s):

Koller M, Fatti G, Chi BH, Keiser O, Hoffmann CJ, Wood R, Prozesky H, Stinson K, Giddy J, Mutevedzi P, Fox MP, Law M, Boulle A, Egger M.

Pub Title:

Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings.

Pub Date:

Nov 1 2015

Journal:

Title: 
JAIDS- Journal of Acquired Immune Deficiency Syndromes
Link: 
http://ovidsp.tx.ovid.com/sp-3.18.0b/ovidweb.cgi?QS2=434f4e1a73d37e8c54b7bccef7797d0c4fd1f0a908785f6b58f6151fd303d79c59db5070c6ba87799032751d58af151148a53aeb578fc5dbb77bc5a83fed1d4e124e578cc1a5dec10697bdcfa07aed94c90d98a6cb67c876bf54e1c4795fcf25fa57027ba4

PubMed: 26470034
Pub PDF: PDF icon Publication.pdf

BACKGROUND:

HIV-1 RNA viral load (VL) testing is recommended to monitor antiretroviral therapy (ART) but not available in many resource-limitedsettings. We developed and validated CD4-based risk charts to guide targeted VL testing.

METHODS:

We modeled the probability of virologic failure up to 5 years of ART based on current and baseline CD4 counts, developed decision rules for targeted VL testing of 10%, 20%, or 40% of patients in 7 cohorts of patients starting ART in South Africa, and plotted cutoffs for VL testing on colour-coded risk charts. We assessed the accuracy of risk chart-guided VL testing to detect virologic failure in validation cohorts from South Africa, Zambia, and the Asia-Pacific.

RESULTS:

In total, 31,450 adult patients were included in the derivation and 25,294 patients in the validation cohorts. Positive predictive values increased with the percentage of patients tested: from 79% (10% tested) to 98% (40% tested) in the South African cohort, from 64% to 93% in the Zambian cohort, and from 73% to 96% in the Asia-Pacific cohort. Corresponding increases in sensitivity were from 35% to 68% in South Africa, from 55% to 82% in Zambia, and from 37% to 71% in Asia-Pacific. The area under the receiver operating curve increased from 0.75 to 0.91 in South Africa, from 0.76 to 0.91 in Zambia, and from 0.77 to 0.92 in Asia-Pacific.

CONCLUSIONS:

CD4-based risk charts with optimal cutoffs for targeted VL testing maybe useful to monitor ART in settings where VL capacity is limited.

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Koller M, Fatti G, Chi BH, Keiser O, Hoffmann CJ, Wood R, Prozesky H, Stinson K, Giddy J, Mutevedzi P, Fox MP, Law M, Boulle A, Egger M. Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings. J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):e110-9. doi: 10.1097/QAI.0000000000000748. PubMed PMID: 26470034.